Ten-Eleven-Translocation 2 (TET2) is an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) and thereby alters the epigenetic state of DNA; somatic loss-of-function mutations of TET2 are frequently observed in patients with diverse myeloid malignancies. To study the function of TET2 in vivo, we analyzed Ayu17-449 (TET2 trap ) mice, in which a gene trap insertion in intron 2 of TET2 reduces TET2 mRNA levels to about 20% of that found in wild-type (WT) mice. TET2 trap/trap mice were born at Mendelian frequency but died at a high rate by postnatal day 3, indicating the essential role of TET2 for survival. Loss of TET2 results in an increase in the number of hematopoietic stem cells (HSCs)/progenitors in the fetal liver, and TET2
INTRODUCTION
Myeloproliferative neoplasms (MPNs) are characterized by an overproduction of white blood cells and are frequently associated with a somatic Janus kinase 2 (JAK2) V617F mutation that results in a constitutively active protein. [1] [2] [3] [4] The presence of JAK2 V617F alone can cause MPN in mouse models, [5] [6] [7] [8] [9] but does not confer a growth advantage upon hematopoietic stem cells (HSCs). 9 In female MPN patients tested for JAK2 mutations and X-chromosomal clonality, the percentage of granulocytes and platelets with a JAK2 mutation was often markedly lower than the percentage of clonal granulocytes. 10, 11 In addition, JAK2-V617F-positive MPNs are frequently found in patients with JAK2-V617F-negative acute myeloid leukemia. 12 These data suggest that the MPN cells expand clonally before acquisition of a JAK2 mutation, and that the leukemic transformation shares a common clonal origin in MPN and acute myeloid leukemia.
Mutations in Ten-Eleven-Translocation-2 (TET2) have also been observed in 10-20% of patients with MPN, 13, 14 as well as in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia, [14] [15] [16] [17] suggesting that mutation of TET2 is a common pathogenetic event in myeloid malignancies. TET family members share a highly conserved catalytic domain, and both TET1 and TET2 catalyze the conversion of 5-methylcytosine into 5-hmC, [18] [19] [20] resulting in the modification of DNA. The amount of 5-hmC in DNA from patients with myeloid malignancies was lower when they possessed a TET2 mutation than when they did not, 19 suggesting that the mutant TET2 protein was defective in its enzymatic function. Recent work has shown that small hairpin RNA-mediated depletion of TET2 in murine hematopoietic precursors alters their differentiation toward monocyte/macrophage lineages in vitro, suggesting a role for TET2 in regulating hematopoiesis. 19 In order to clarify the function of TET2 in hematopoiesis in vivo, we analyzed Ayu17-449 mice, in which a gene trap vector was inserted into intron 2 of TET2.
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MATERIALS AND METHODS Mice
Ayu17-449 mice were generated at Kumamoto University and were described previously. 21 We obtained the mice from the mutant mouse resource of Trans Genic Inc. (Kobe, Japan). A gene trap vector containing a splice acceptor followed by the b-galactosidase/neomycin resistance fusion cassette disrupts the TET2 gene locus by inserting into intron 2 ( Figure 1a ). We hereafter refer to this allele as TET2 trap . The mice were genotyped by tail DNA PCR using 5 0 -AGCAGAGATGAGAGTCTTGG-3 0 and 5 0 -TGTGAGTACAGATCATGGAGC-3 0 (primers recognizing intron 2) to detect the WT TET2 allele (708 bp), and 5 0 -CTGAATGAACTGCAGGACGAG-3 0 and 5 0 -GTCCAGATCATCCTGATCGAC-3 0 (primers recognizing the b-galactosidase/neomycin resistance fusion cassette sequence) to detect TET2 trap allele (309 bp). The strain was backcrossed at least eight times onto the C57BL/6N (B6-CD45.2) background for this study. B6-CD45.2 mice were purchased from Japan SLC, Inc. (Shizuoka, Japan). Mice congenic for the CD45.1 locus (B6-CD45.1) were bred and maintained at Sankyo Lab Service (Tsukuba, Japan). Animal studies were performed in accordance with the local Miyazaki University Ethics Committee.
Southern blot analysis
Tail DNA from TET2 trap/ þ mice was digested with either EcoRI or SacI, and electrophoretically separated on a 0.8% agarose gel. After transfer to a nylon membrane, the digested DNA was hybridized with a probe A or probe B, indicated in Figure 1a .
Quantitative and semi-quantitative reverse transcriptase PCR RNA was extracted using the RNeasy mini kit (QIAGEN, Valencia, CA, USA). For semi-quantitative PCR, reverse transcription was carried out with 1 250 ng of total RNA using a TaKaRa RNA PCR kit (Takara Bio Inc., Otsu, Japan). Semi-quantitative PCR was performed using the following primers: TET2 (exon 1-3 
Flow cytometric analysis
Aliquots of 1 Â 10 6 cells were stained with conjugated monoclonal antibodies. Cells were washed in phosphate-buffered saline þ 1% fetal bovine serum, blocked with Fc-block (BD PharMingen, San Diego, CA, USA) for 4 min on ice, and stained with monoclonal antibodies in phosphatebuffered saline þ 1% fetal bovine serum for 40 min on ice. Antibodies used were fluorescein isothiocyanate-conjugated CD71, B220, CD41, CD4 and Mac-1, phycoerythrin-conjugated TER119, CD19, CD3,Gr-1 and CD45.1, peridinin chlorophyll protein-Cy5.5-conjugated CD45.2, allophycocyaninconjugated immunoglobulin M, CD8 and CD117 anti-mouse antibodies (BD PharMingen). After washing, cells were resuspended in phosphatebuffered saline þ 1% fetal bovine serum and analyzed with a fluorescenceactivated cell sorting Calibur cytometer (BD Biosciences, San Jose, CA, USA). At least 20 000 events were acquired. For progenitor analysis, biotinconjugated CD3, CD4, CD8, CD19, B220, Mac-1, Gr-1 and Ter119 (Mac-1was removed from the mixture for the FL) antibodies (eBioscience, San Diego, CA, USA) were used for lineage determination. Antibodies for progenitor cell staining were Alexa488-conjugated CD150, Pacific blue-conjugated CD48, eFluor450-or biotin-conjugated interleukin-7R, allophycocyaninconjugated CD117, fluorescein isothiocyanate-conjugated CD34, phycoerythrin-or biotin-conjugated Sca-1 and phycoerythrin-Cy7-conjugated CD16/32 (eBioscience). Biotin-conjugated antibody was detected with streptavidin-allophycocyanin-Cy7. Cells were analyzed using a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany). Data were analyzed using Flowjo software (Tree Star, Ashland, OR, USA).
Colony formation assay
To detect colony-forming units-erythroid (CFU-E) colonies, 1 Â 10 4 FL cells or 1 Â 10 5 BM cells were plated in methylcellulose (M3234; StemCell Technologies Inc, Vancouver, BC, Canada) in the presence of 3 U of erythropoietin (EPO). To detect other colony types, burst-forming unitserythroid (BFU-E), CFU-granulocyte-macrophage and CFU-granulocyte, erythrocyte, monocyte and megakaryocyte (CFU-GEMM), 2 Â 10 4 FL or BM cells were plated in methylcellulose (M3434; StemCell Technologies Inc.) containing 3 U/ml EPO, 10 ng/ml recombinant murine interleukin-3, 10 ng/ml recombinant murine interleukin-6 and 50 ng/ml recombinant murine stem cell factor according to the manufacturer's protocols. CFU-E was counted on day 3 and other colonies were counted on day 7.
Pathological examination
For histological evaluation, tissue samples were fixed in formalin, paraffin-embedded and sectioned for hematoxylin and eosin staining or Gomori silver staining according to standard protocols. 21 in which a gene trap vector was inserted into intron 2 of TET2 (Figure 1a) . The expected single 4.8-kb band was detected on a Southern blot of tail DNA digested with EcoRI and hybridized with probe A (Figure 1b (Table 1 ). The proportion of TET2 trap/trap mice at P0 and P3 was 33% and 8%, respectively.
There are four published models of TET2-deficient mice: one that conditionally deletes exon 3, another that conditionally deletes exon 11 and two that delete exons 7 À 11. [22] [23] [24] [25] All in these studies, mutants were born at the expected Mendelian ratio and grew into adults. As our TET2 trap mice were backcrossed at least eight times onto the C57BL/6 (B6-CD45.2) background, we generated TET2 trap/trap mice on a mixed C57BL/6 and Balb/c background. Unlike TET2 trap/trap mice on the C57BL/6 background, mutants on the C57BL/6 and Balb/c background survived 412 weeks (Table 1) .
We first examined whether TET2 mRNA was expressed in TET2 trap mice. Semi-quantitative reverse transcriptase PCR analysis for TET2 was performed using FL cells at embryonic day 14.5. To examine the whole length of TET2 mRNA, amplification reactions were performed for exon 1-3, exon 3-5, exon 6-8 and exon 9-11. Despite the insertion of the trap vector, low expression of TET2 mRNA was found in all parts in TET2 trap/trap FL cells (Figure 1c ). Real-time PCR using the primers in exon 9 and 10 revealed that (Figure 2c ). There is no difference in the formation of CFU-GEMM, BFU-E or CFU-E between WT FL cells and TET2 trap/trap FL cells. We next transplanted FL cells from WT or TET2 trap/trap mice into lethally irradiated recipient mice, and examined their hematological parameters. There were no significant differences in the blood counts between the two groups 20 weeks after transplantation (Figure 3a) . Flow cytometric analysis revealed that the proportion of Gr-1 þ /Mac1 þ cells was higher in recipient mice transplanted with TET2 trap/trap FL cells compared with those transplanted with WT FL cells (Figure 3b) . A differential count of peripheral blood in recipient mice transplanted with TET2 trap/trap FL cells showed an increase in the monocyte number (Figure 3c ).
In BM compartments including Lin
, there were no significant differences between the two groups (Table 2) . Interestingly, TET2 trap/trap BM cells exhibited an increase in colonyforming ability in vitro. In recipient mice transplanted with TET2 trap/trap FL cells, the CFU-granulocyte-macrophage of BM cells was increased by 50% compared with recipient mice transplanted with WT FL cells (Po0.01) (Figure 3d ). There were no differences in CFU-GEMM, BFU-E and CFU-E between the two groups.
Recipient mice transplanted with TET2 trap/trap FL cells showed a mild splenomegaly (Figure 4a ). The spleen weights in recipient mice transplanted with WT FL cells and TET2 trap/trap FL cells were 0.076 ± 0.003 and 0.092 ± 0.005 g, respectively (P ¼ 0.02). The normal splenic architecture was destroyed by hematopoietic cell infiltration, and perivascular infiltration of myeloid cells in liver and lung was observed in recipient mice transplanted with TET2 trap/trap FL cells (Figure 4b ). The proportion and number of CD71 þ TER119 þ erythroid cells, CD41 þ megakaryocytes, LSK and Table 2 ). In addition, the CFU-granulocyte-macrophage was higher in spleens from TET2 trap/trap mice, whereas the CFU-GEMM, BFU-E and CFU-E did not differ between TET2 trap/trap and WT mice (Figure 4d ). 
. Frequency and absolute number of cells in various hematopoietic compartments (means±s.e.). *P o0.05, by unpaired 2-tailed Student's t test. þ /Mac1 þ cells and B220 þ cells was 490% in secondary recipient mice, whereas that among CD4 þ /CD8 þ cells was 64%. It should be noted that these percentages were consistently higher than observed in recipient mice transplanted with WT cells (Figure 5b) . Thus, TET2 trap/trap HSCs exhibit increased self-renewal ability in vivo.
DISCUSSION Here, we demonstrate that FL cells from E14.5 TET2 trap/trap mice express low levels of TET2 mRNA (20% of WT). Decreasing TET2 diminishes genomic 5-hmC levels in all organs tested, especially in spleen. We show here that in addition to being important for hematopoiesis and myeloid transformation, TET2 is essential for survival after birth. TET2 trap/trap mice on the C57BL/6 background were born at the expected Mendelian frequency, but died at a high rate by P3. On the other hand, TET2 trap/trap mice on a C57BL/6 and Balb/c mixed background survived 412 weeks. This indicates that TET2 may regulate genes that are essential for survival during the early postnatal period and that differ in expression levels between the C57BL/6 and Balb/c backgrounds. Indeed, Li et al. 26 recently reported that many genes in the complement and coagulation cascade, metabolism, biosynthesis, transcriptional regulation, proteolysis and intracellular signaling pathways were affected by the loss of TET2.
Previous work showed that TET2 trap/trap mice had a fewer acidic granules in the proximal convoluted tubules of the kidney compared with WT, suggesting a role for TET2 in granule formation in the kidney that might underlie the postnatal lethality. 21 However, we observed no abnormalities in kidneys from TET2 trap/trap mice (Supplementary Figure S1) . Acidic granules in the proximal convoluted tubules of the kidneys in TET2 trap/trap mice were observed as is the case in those in WT mice. Renal function appeared normal in these mutants, with no differences in the serum concentrations of sodium, potassium, chloride, blood urea nitrogen and blood pH between TET2 trap/trap and WT pups (Supplementary Table S1 ). Thus, it is unlikely that kidney malfunction is the cause of in TET2 mutants on the C57BL/6 background. In addition, there are no gross abnormalities in the liver, intestine, pancreas, heart, lung and brain between WT and TET2 trap/trap mice (Supplementary Figure S1) . The cause of the perinatal lethality of TET2 mutants is unclear at present.
Another important function of TET2 is to regulate the homeostasis of HSCs. The competitive repopulation assay using FL cells from TET2 trap/trap mice indicated that decreased TET2 levels resulted in increased self-renewal activity in stem/progenitor cells. This result was consistent with the recently reported studies using adult BM cells from TET2 conditional knockout mice. [22] [23] [24] [25] Thus, TET2 appears to function cell autonomously, with the loss of TET2 likely conferring a proliferative advantage to FL cells in vivo. The increased self-renewal activity in cells with TET2 loss-of-function mutations might be responsible for the initiation of MPN. We and others previously reported that JAK2 V617F transgenic and knockin mice develop MPN, [5] [6] [7] [8] [9] and transplantation experiments demonstrated that JAK2 V617F cells function cell autonomously to induce MPN. However, JAK2 V617F LSK cells have a little selective advantage over JAK2 WT LSK cells in competitive transplant experiments. 9 Nonetheless, a selective growth advantage of leukemia-initiating cells is required for the initiation of MPN. We show here that TET2 mutation confers a selective growth advantage to stem/progenitor cells, and leads to the clonal expansion of mutated cells. This is consistent with xenotransplantation studies in which TET2 mutant cells from MPN patients engrafted into nonobese diabetic/severe combined immunodeficient (NOD-SCID) mice, 13 but JAK2 V617F cells from polycythemia vera patients rarely did. 27 The precise mechanism of hematopoietic cell clonal expansion by loss of TET2 function remains unknown at this point. As TET2 modifies DNA by catalyzing the addition of a hydroxyl group to 5-methylcytosine, 20 and this enzymatic activity is deficient in patients with TET2 mutations, 19 impaired DNA 5-hydroxymethylation may be crucial for stem cell self-renewal and expansion. Thus, disturbance of the epigenetic control of gene expression critical for stem cell homeostasis by TET2 might underlie the ontogeny of myeloid malignancies. However, further study is required to identify the genes that are modified by TET2 and regulate HSC homeostasis.
We also find here that in contrast to the extensive myeloproliferative phenotype in JAK2 V617F mice, 5-9 the analysis of recipient mice transplanted with TET2 trap/trap FL cells exhibited only mild monocytosis, splenomegaly and extramedullary hematopoiesis compared with recipient mice transplanted with WT FL cells. Moreover, there were no significant differences in peripheral blood counts between the two groups. In other words, TET2 trap/trap mice exhibited very mild myeloproliferation in vivo compared with JAK2 V617F mice. Notably, TET2 conditional knockout mice exhibit leukocytosis, neutrophilia, monocytosis and splenomegaly, features characteristic of human chronic myelomonocytic leukemia. [22] [23] [24] [25] The residual levels of TET2 in our TET2 trap/trap mice may account for this difference in myeloproliferative features. However, even complete loss of TET2 results in a much milder MPN phenotype than observed in JAK2 V617F mice. Thus, TET2 loss-of-function mutations may contribute less to MPN phenotypes than the JAK2 V617F mutation.
In summary, our data indicate the essential role of TET2 for survival and for the regulation of HSC self-renewal. Loss of TET2 function confers a growth advantage over WT to hematopoietic cells and leads to clonal expansion both of which are implicated in the pathogenesis of myeloid malignancies.
